An Evaluation of the Safety and Efficacy of Nitazoxanide on Collagen Turnover in NASH Patients With Fibrosis

NCT03656068 PHASE2 COMPLETED Results posted

To evaluate the safety and tolerability of Nitazoxanide (NTZ) 500mg Twice Daily (BID) after 24 weeks of treatment in patients with NASH induced Stage 2 or Stage 3 fibrosis

Details

Lead sponsor	Pinnacle Clinical Research, PLLC
Phase	PHASE2
Status	COMPLETED
Enrolment	21
Start date	Tue Dec 04 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Wed Nov 25 2020 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Non-alcoholic Steatohepatitis
• Fatty Liver
• Fibrosis, Liver
• Compensated Cirrhosis

Interventions

• Nitazoxanide 500mg BID

Countries

United States